GuidesNamesLast checked August 24, 2026No dosing

GLP-1, "GLP-2" and "GLP-3": what people actually mean, and what you can get

There's no GLP-2 or GLP-3 weight-loss drug. The newer ones aren't later versions of GLP-1, they act on more receptors at once. Here's what each one is, and what's real in Canada.

This field moves faster than almost any other in medicine, so check again before you decide anything.

One receptor, two, threeAverage weight loss at the highest studied dose, each drug's own trials
SemaglutideOzempic, Wegovy · “GLP-1”GLP-1GIPGCG~14–15% trial weight loss · Approved in Canada
TirzepatideMounjaro, Zepbound · “GLP-2”GLP-1GIPGCG~20–21% trial weight loss · Approved in Canada
Retatrutideno brand · “GLP-3”GLP-1GIPGCG~28% trial weight loss · Still in trials
GLP-1: appetite and insulinGIP: fat tissue and tolerabilityGlucagon (GCG): energy expenditure
Not head-to-head. Different trials enrol different people for different lengths of time, so the bars rank the drugs less precisely than they look. The same caveat applies to every figure on this page.

First, the naming, because it trips almost everyone up.

There's no "GLP-2" or "GLP-3" weight-loss drug. The newer medications aren't later versions of GLP-1, they act on more receptors at once. A single agonist hits GLP-1. A dual agonist adds a second target. A triple adds a third.

GLP-2 does exist as a hormone, and there's a real GLP-2 drug, teduglutide, but it treats short bowel syndrome and has nothing to do with weight. GLP-3 isn't a thing at all. If a seller offers you "GLP-3", they don't know what they're selling.

The three generations people are usually talking about

DrugYou may know it asWhat it acts onTrial loss
SemaglutideApproved in CanadaOzempic, Wegovy, Rybelsus · the original “GLP-1”Single agonist: GLP-1 onlyApproved and stocked. Generics since April 2026.~14–15%
TirzepatideApproved in CanadaMounjaro, Zepbound · usually what “GLP-2” meansDual agonist: GLP-1 + GIPApproved and stocked. No generic.~20–21%
RetatrutideStill in trialsNo brand name (it isn't on sale) · usually what “GLP-3” meansTriple agonist: GLP-1 + GIP + glucagonNot approved anywhere. Phase 3. Lilly planned an FDA filing in Q4 2026.~28%

The quoted names in the second column are what people say, not what these are. I put them in the table because that's how most readers arrive, and finding yourself in a table beats being corrected before you've got your bearings.

Percentages are average weight loss from each drug's own trials at the highest studied dose. They're not head-to-head except where noted. Different trials enrol different people for different lengths of time, and comparing across them overstates how precisely they can be ranked.

What each receptor does

It's worth understanding this properly, because the drugs differ in what they do, not just in how strong they are.

GLP-1, the appetite and insulin one (semaglutide, the original "GLP-1")

GLP-1 is a hormone your gut releases when food arrives. A GLP-1 drug is a long-lasting copy of it, and it does four things at once:

  • Tells the pancreas to release insulin only when blood glucose is high. That glucose-dependence is why these rarely cause hypoglycaemia, unlike older diabetes drugs that push insulin regardless.
  • Suppresses glucagon, which would otherwise raise blood sugar.
  • Slows stomach emptying, so a meal sits longer and fullness lasts. This is also where most of the nausea comes from.
  • Acts directly on appetite centres in the brain. This is the part people describe as the "food noise" going quiet. It isn't willpower, it's the constant background pull toward eating switching off.

+ GIP, the fat-tissue and tolerability one (tirzepatide, what people call "GLP-2")

GIP is the other incretin, released from a different part of the gut. Adding it (tirzepatide) contributes more glucose-dependent insulin release, but the interesting effects are elsewhere. GIP acts on fat tissue itself, and appears to improve how efficiently it stores and buffers incoming fat, and with it insulin sensitivity.

It may also act in the brain to reduce nausea, which is the leading explanation for something otherwise odd: tirzepatide is both more effective than semaglutide and frequently better tolerated. In a direct trial, 20.2% against 13.7%.

There's an honest wrinkle here that shows how young this science is: drugs that block the GIP receptor also produce weight loss. MariTide pairs a GLP-1 agonist with a GIP antagonist, and it works. Why both directions help isn't fully explained, and anyone confidently telling you why GIP works is ahead of the evidence.

+ glucagon, the burn-it-off one (retatrutide, what people call "GLP-3")

This is the counterintuitive addition. Glucagon is insulin's opposite, it raises blood sugar, which sounds like the last thing you'd want in a diabetes or obesity drug. Two things make it worth including anyway:

  • It increases energy expenditure. Every drug above works mainly by reducing intake. Glucagon adds the other side of the equation, burning more and not only eating less, which is most likely why retatrutide's numbers step up rather than inch up.
  • It drives the liver to burn its own fat. That's the direct explanation for the liver results below, and it's a different mechanism from losing weight and having the liver improve as a consequence.

The engineering trick is the pairing. Glucagon pushes glucose up, GLP-1 pulls it down. Combined in the right ratio, you keep the energy-expenditure and liver effects while the glycaemic penalty cancels out. That balance is the whole design, and it's also why dosing a triple agonist is harder than dosing a single one. Get the ratio wrong and the glucose control goes with it.

What each of those costs you

Side effects follow the mechanisms directly, which is why they get worse in roughly the order above. The gastrointestinal effects all come downstream of slowed stomach emptying, the same action that produces the fullness. So they aren't a separate problem you might avoid, they're the treatment being felt.

DrugMost commonHeart rateWorth knowing
SemaglutideNausea (~44%), diarrhoea (~30%), vomiting (~24%), constipation (~24%)+3–5 bpmThe GI effects are the slowed gastric emptying being felt. Worst on the way up.
TirzepatideNausea (~25–30%), diarrhoea (~23%), vomiting (~13%), constipation (~11%)+2–5 bpmConsistently lower GI burden despite being the stronger drug. The leading explanation is the hypothesis that GIP reduces nausea.
RetatrutideNausea (~43% at 12 mg), plus the same diarrhoea/vomiting/constipation pattern+5–10 bpmThe heart-rate rise is the largest of the three and is attributed to glucagon, which speeds the heart directly. About 21% reported dysesthesia (odd skin sensations, tingling) at 12 mg, and that isn't a feature of the other two.

Rates are from each drug's own trials at the highest dose, and they aren't comparable across columns for the same reasons the weight figures aren't. Almost all of it is worst during dose increases and settles at a steady dose. That's the practical argument for titrating slowly, and the reason people who rush it conclude they can't tolerate a drug they could have tolerated.

Rare but serious, and shared across the class: pancreatitis, gallbladder disease (more likely with rapid weight loss), and a thyroid C-cell tumour signal from rodent studies. That signal hasn't been established in humans, but it keeps these contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2.

The one that's a pill

Orforglipron isn't more powerful, its trial weight loss sits below injectable semaglutide. What it changes is the barrier: it's a small-molecule tablet with no food or water timing restrictions, and no cold chain. The FDA approved it in April 2026 as Foundayo. Health Canada has it under review, with approval plausibly late 2026 or 2027. For people who won't inject, a drug they'll actually take beats a stronger one they won't.

Retatrutide, and why the numbers aren't the whole story

Retatrutide is not approved anywhere in the world, even though its Phase 3 results are the largest ever recorded for an obesity drug: around 28% average weight loss, with a substantial share of participants losing over 30%. Lilly planned to file with the FDA in Q4 2026. A 10 to 12 month review puts plausible US approval in late 2027 and launch in 2028, and Canada typically comes behind that.

The early results beyond weight, and they're early

The weight number gets the attention, but the trial programme is testing it across several conditions at once, and some of what has been reported is more interesting than the scale reading:

  • Fatty liver disease (MASLD). A Phase 2a trial published in Nature Medicine reported liver fat falling by around 82% at 24 weeks on the highest dose, with 86% of participants reaching a normal liver-fat level (under 5%), and up to 86% reduction by 48 weeks. That's the glucagon arm doing what glucagon does. A dedicated Phase 3 is running.
  • Knee osteoarthritis pain. TRIUMPH-4, the first Phase 3 to report, paired 28.7% weight loss with roughly 75% pain reduction at 68 weeks. This trial can't separate how much of that is load coming off the joint versus anything else.
  • Sleep apnoea, type 2 diabetes, cardiovascular outcomes. All under study within the same programme, with further readouts expected through 2026.

Hold all of this loosely. The liver result is Phase 2a: small, early, and the stage at which drugs most often look better than they turn out to be. Cardiovascular outcome trials, the ones that take years and actually count events, haven't reported. Impressive early findings are how most promising drugs look right before the larger trials either confirm them or don't, and a good number don't.

So anything sold as retatrutide today is an unapproved drug from an unregulated supplier, with no verified purity or concentration and no recourse if a vial is wrong. The trial numbers came from pharmaceutical-grade material under medical supervision, they aren't a claim about what's in a vial bought online. That gap is the entire risk, and you can't see it from the outside.

One person's nineteen weeks on it, drawn from a real record and rebuilt every night, is the retatrutide diary. It says what they took, not what you should.

The lesser-known ones, which is where the 1-2-3 idea falls apart

None of these fit a numbered sequence. One is a GLP-1 in a tablet. One pairs a GLP-1 with a hormone system that isn't on the list at all. One is a dual agonist with a different second target from tirzepatide's. They aren't a later generation of anything, they're different combinations being tried at the same time.

DrugYou may know it asWhat it acts onTrial loss
OrforglipronUnder reviewFoundayo · the GLP-1 pillSingle agonist: GLP-1, but a tablet rather than an injectionNot approved. Under Health Canada review, with approval plausibly late 2026–2027.~11–12%
CagriSemaUnder reviewNo brand name yetSemaglutide + cagrilintide, a GLP-1 plus an amylin analogue, which is a different hormone system againNot approved. Filed with the FDA Dec 2025, and a US decision was expected late 2026.~22–23%
SurvodutideStill in trialsNo brand name yetDual agonist: GLP-1 + glucagon, a different pair from tirzepatide'sNot approved. Phase 3 is running, and approval is projected 2027–2028 at the earliest.~19% (Phase 2)

What this means if you're choosing today

In Canada, right now, the real choice is between semaglutide (cheapest by a distance since generics landed) and tirzepatide (more effective, no generic, more expensive). Everything else on this page is a reason to revisit the decision in a year, not an option available this month. Waiting for a better drug has a real cost too, the years spent waiting are years untreated, and that tradeoff belongs to you and your prescriber, not to a table.

Prices and access for what you can get in Canada are in my cost and access guide.

Selfsense

If you're already on one of these, Selfsense tracks your doses, sites and weight against every dose change, so the nausea on the way up and the plateau later are on one picture.

Open your record →

General information, not medical advice, and not a recommendation of any treatment. Trial results describe averages in studied populations, not what will happen to you. Prescribing decisions belong to you and a licensed healthcare professional.